Medtronic (NYSE:MDT) touted data today from an at-home pediatric study of its MiniMed 670G hybrid closed-loop diabetes management system.
The company’s study included 105 kids, ages 7 to 13, and found that patients spent more time in the target blood glucose range, had less glycemic variability and experienced less hypo- and hyperglycemia compared to baseline data. Data from the pediatric study was included as part of an application to the FDA, as Medtronic looks to expand MiniMed’s indication to include children between the ages of 7 and 13.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic looks to expand MiniMed 670G into pediatric diabetes appeared first on MassDevice.
from MassDevice http://ift.tt/2Eud2Tr
Cap comentari:
Publica un comentari a l'entrada